Trials / Completed
CompletedNCT00195234
Study Evaluating Vaccine in Adults With HIV
A Phase 1 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of an HIV CTL Multi-Epitope Peptide Vaccine Formulated With RC529-SE and GM-CSF Given to HIV-1 Positive Adults on Stable HAART.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (planned)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to learn whether the study vaccine and adjuvants (drugs that are used to help improve immune responses) have an acceptable safety profile in treating individuals with HIV. A second purpose of this study is to understand how the immune system responds to the study vaccine and adjuvants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | HIV CTL MEP 1000 micrograms, 19 months per subject |
Timeline
- Start date
- 2004-12-01
- Completion
- 2007-02-01
- First posted
- 2005-09-19
- Last updated
- 2007-12-05
Locations
10 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00195234. Inclusion in this directory is not an endorsement.